TOKYO & HAMBURG, GERMANY & CENTER VALLEY, PA.-- May 28, 2021 -- Olympus Corporation (”Olympus” - Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) announced today that it has finalized the acquisition of Israeli medical device company Medi-Tate Ltd. (“Medi-Tate” - CEO: Ido Kilemnik) following the announcement of its decision to exercise the call option in February, 2021. Through this acquisition, Olympus expands its business line in offering in-office treatment for benign prostatic hyperplasia (BPH) treatment and solidifies its position as a leader in the field of urological devices.

Medi-Tate is a medical device manufacturer engaged in the research and development, production, and sale of devices for the minimally invasive treatment of BPH. The company’s flagship product “iTind” has received U.S. FDA de Novo authorization and a European CE mark. With its initial Medi-Tate investment, Olympus has had the right of distribution since November 2018.

The incidence of BPH, one of the most common diseases in aging men and the most common cause of lower urinary tract symptoms (“LUTS”), is expected to increase as the general global population gets older. According to the American Urological Association, BPH is a condition that nearly 80% of men will face in their lifetime and that ratio is higher in older ages.ⅰ Medication and surgical treatment have been among the usual treatment options for BPH, and in recent years, more minimally invasive surgical treatment devices have come to the market.

Olympus is a market leader providing devices for BPH treatment such as resectoscopes and a wide variety of electrodes. By adding the non-ablative BPH treatment device iTind, which allows patients to maintain their sexual function, to its portfolio, Olympus can provide urologists more treatment options according to the symptoms and needs of their patients, ranging from in-offices day treatment to surgical therapies in hospitals.

Nacho Abia, Chief Operating Officer of Olympus Corporation, said, “the acquisition of Medi-Tate aligns with our corporate strategy of focusing on three priority therapeutic areas within our Therapeutic Solutions Division — gastroenterological endotherapy devices, urological devices and respiratory endotherapy devices. Medi-Tate’s innovative products offer a truly minimally invasive treatment option for patients and flexibility in the delivery of care for healthcare professionals.”

Ido Kilemnik, Chief Executive Officer of Medi-Tate, commented, “We believe Olympus appreciates our focus on long-term clinical results and dedication of the entire Medi-Tate team. We are pleased to be joining Olympus, which shares our vision of making iTind the global standard for BPH treatment. We are excited to be collaborating with Olympus in our effort to enhance the patients’ quality of life.”

Minimally invasive treatment enabled by iTind

iTind, a temporarily implanted nitinol device, supports the relief of lower urinary tract symptoms (LUTS) due to BPH. The iTind treatment is performed by an urologist in an outpatient hospital, ambulatory surgery center or in a physician’s office, where the iTind device is placed in the prostate in a folded configuration. The device slowly expands and exerts gentle pressure at three precise points to reshape the prostatic urethra and bladder neck. After five to seven days, the device is completely removed, leaving a wider opening through which urine can flow for the relief of BPH symptoms.